What are the recommended starting doses and considerations for switching a patient who poorly tolerated Vyvanse (lisdexamfetamine) 50 mg to Mydayis (mixed amphetamine salts) or Focalin XR (dexmethylphenidate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switch to Focalin XR as the First-Line Alternative

Given that Vyvanse (lisdexamfetamine) 50 mg provided therapeutic benefit but tolerability issues arose from formulation changes, switch to Focalin XR (dexmethylphenidate) starting at 20 mg once daily, as this represents a class change from amphetamine to methylphenidate that may avoid similar tolerability concerns while maintaining efficacy.

Rationale for Choosing Focalin XR Over Mydayis

Why Focalin XR is the Better Choice

Switching medication classes is preferable when a patient experiences tolerability issues with an amphetamine-based stimulant. Since Vyvanse is an amphetamine prodrug and the patient had problems (even if related to formulation changes), moving to a methylphenidate-based medication like Focalin XR provides a mechanistically different option 1.

  • Focalin XR offers the active d-isomer of methylphenidate at half the dose of racemic methylphenidate, potentially reducing side effects while maintaining efficacy 2
  • Duration of action is 10-12 hours, comparable to Vyvanse's coverage 1
  • The bimodal release mechanism (50% immediate, 50% at 4 hours) provides smooth symptom control throughout the day 3

Why Not Mydayis First

Mydayis is a triple-bead mixed amphetamine salt formulation—it's still an amphetamine product, just like Vyvanse. While it has a different release profile (up to 16 hours), staying within the amphetamine class when the patient already had issues with Vyvanse may perpetuate similar tolerability problems 4. The guideline framework supports trying a different stimulant class when the first choice is problematic 5.

Specific Dosing Strategy for Focalin XR

Starting Dose Conversion

For a patient on Vyvanse 50 mg who had therapeutic benefit, start Focalin XR at 20 mg once daily 1. This represents a moderate starting dose that:

  • Accounts for the patient's demonstrated response to stimulants
  • Provides room for upward titration if needed
  • Minimizes risk of under-dosing (a common clinical pitfall 6)

Titration Protocol

Adjust dose in 5 mg increments weekly based on symptom control and tolerability 1:

  • Week 1: 20 mg daily
  • Week 2: 25 mg if inadequate response
  • Week 3: 30 mg if needed
  • Maximum dose: 40 mg daily (FDA-approved maximum for adults) 1

The key principle: titrate to optimal symptom control without dose-limiting adverse effects 6. Recent meta-analytic evidence demonstrates that flexible-dose titration strategies produce superior outcomes compared to fixed dosing, with continued efficacy gains across the FDA-approved dose range 6.

If Focalin XR Fails: Then Consider Mydayis

Should Focalin XR prove inadequate after proper titration (4-6 weeks at optimal dose), then Mydayis becomes a reasonable second-line option:

Mydayis Dosing

  • Start at 12.5 mg once daily (standard starting dose for amphetamine-naive or switching patients) 4
  • Titrate in 12.5 mg increments weekly
  • Target range: 12.5-25 mg daily
  • Maximum: 25 mg daily in most patients

Mydayis Advantages Over Vyvanse

  • Different release mechanism (triple-bead vs. prodrug) may provide more consistent absorption
  • Longer duration (up to 16 hours) may reduce end-of-day symptom rebound
  • Less dependent on individual enzymatic conversion compared to lisdexamfetamine's prodrug mechanism 7

Critical Monitoring Parameters

Initial Assessment (Before Switching)

  • Blood pressure and pulse (quarterly monitoring required for adults on stimulants) 5
  • Weight (stimulants commonly cause appetite suppression)
  • Cardiovascular history (rule out structural abnormalities) 1

Ongoing Monitoring

  • Weekly during titration: ADHD symptom ratings, side effects (insomnia, appetite, irritability)
  • Monthly once stable: Symptom control, blood pressure, pulse, weight
  • Quarterly: Comprehensive reassessment of need for continued treatment 1

Common Pitfalls to Avoid

  1. Under-dosing: Don't stop at 10 mg Focalin XR assuming equivalence to Vyvanse 50 mg—the patient needs adequate dosing for symptom control 6

  2. Premature switching: Allow 4-6 weeks at optimal dose before declaring treatment failure 1

  3. Ignoring the formulation issue: If the patient's problem was truly retailer-related formulation inconsistency with Vyvanse, document this and ensure pharmacy consistency with the new medication

  4. Not considering non-stimulants: If both methylphenidate and amphetamine classes fail, atomoxetine or guanfacine XR become relevant options 3

Evidence Quality Note

The FDA drug labels for Focalin XR provide the most authoritative dosing guidance 1. The 2002 AACAP guidelines, while older, remain the primary guideline source for stimulant selection strategy 5. Recent meta-analyses support aggressive titration to optimal doses rather than settling for subtherapeutic dosing 6. Head-to-head comparisons between lisdexamfetamine and dexmethylphenidate are limited, but both demonstrate robust efficacy in adults with ADHD 8, 9.

References

Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.